156 results
8-K
EX-10.1
ARAV
Aravive Inc
17 Jan 24
Entry into a Material Definitive Agreement
4:22pm
reimbursements set forth in the Compensation and Expense Reimbursement Agreement dated as of the date hereof between the Assignor and the Assignee (the “Fee Letter
8-K
EX-99.1
ARAV
Aravive Inc
2 Aug 23
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
4:18pm
and reimbursement; potential difficulties enforcing the Company's intellectual property rights; and the Company's reliance on its licensor of intellectual property
8-K
EX-99.1
6vokqtgpe nx
25 May 23
Regulation FD Disclosure
5:00pm
8-K
EX-99.1
56dgrb93el
16 May 23
Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
7:05am
8-K
EX-99.1
ngdbg
10 May 23
Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates
4:05pm
8-K
EX-99.1
9z97c4pn9
11 Apr 23
Aravive Appoints Carolina Petrini as Chief Commercial Officer
7:10am
8-K
EX-99.1
y6zmuxe0b
29 Nov 22
Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
7:05am
8-K
EX-99.1
tvf4zctnc9
10 Nov 22
Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
7:05am
8-K/A
EX-10.1
c3px72 nzf1ggoxb4
28 Oct 22
Other Events
4:05pm
8-K
EX-99.1
arbqmjj 9kdaikizmmk
26 Oct 22
Aravive Announces Approximately $41.5 Million Private Placement Financing
4:35pm
8-K
EX-4.3
aww8oxmd5edeqcu53u5
26 Oct 22
Aravive Announces Approximately $41.5 Million Private Placement Financing
4:35pm
8-K
EX-4.2
r6a8bzbfv4gfcukj
26 Oct 22
Aravive Announces Approximately $41.5 Million Private Placement Financing
4:35pm